Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 199

Similar articles for PubMed (Select 20643915)

1.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

2.

Pharmacological Measures of Adherence and Risk of HIV Acquisition in the VOICE Study.

Dai JY, Hendrix CW, Richardson BA, Kelly C, Marzinke M, Chirenje ZM, Marrazzo JM, Brown ER.

J Infect Dis. 2015 Jun 29. pii: jiv333. [Epub ahead of print]

PMID:
26123563
3.

Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.

Palanee-Phillips T, Schwartz K, Brown ER, Govender V, Mgodi N, Kiweewa FM, Nair G, Mhlanga F, Siva S, Bekker LG, Jeenarain N, Gaffoor Z, Martinson F, Makanani B, Naidoo S, Pather A, Phillip J, Husnik MJ, van der Straten A, Soto-Torres L, Baeten J.

PLoS One. 2015 Jun 10;10(6):e0128857. doi: 10.1371/journal.pone.0128857. eCollection 2015.

4.

Oral and gel tenofovir for genital HSV-2 shedding in immunocompetent women: a double-blind randomized cross-over trial (128/160 chars&spaces).

Bender Ignacio RA, Perti T, Magaret AS, Rajagopal S, Stevens CE, Huang ML, Selke S, Johnston C, Marrazzo J, Wald A.

J Infect Dis. 2015 Jun 4. pii: jiv317. [Epub ahead of print]

PMID:
26044291
5.

Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: a Double-Blind Randomized Trial.

Chen BA, Panther L, Marzinke MA, Hendrix CW, Hoesley CJ, van der Straten A, Husnik MJ, Soto-Torres L, Nel A, Johnson S, Richardson-Harman N, Rabe LK, Dezzutti CS.

J Acquir Immune Defic Syndr. 2015 May 28. [Epub ahead of print]

PMID:
26034880
6.

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.

Ustianowski A, Arends JE.

Infect Dis Ther. 2015 Jun;4(2):145-57. doi: 10.1007/s40121-015-0070-1. Epub 2015 Jun 2.

7.

The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.

Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Curlin ME, Na-Pompet S, Warapronmongkholkul A, Kittimunkong S, Gvetadze RJ, McNicholl JM, Paxton LA, Choopanya K; Bangkok Tenofovir Study Group.

AIDS. 2015 Apr 24;29(7):819-24. doi: 10.1097/QAD.0000000000000613.

PMID:
25985403
8.

Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.

Minnis AM, van der Straten A, Salee P, Hendrix CW.

AIDS Behav. 2015 May 13. [Epub ahead of print]

PMID:
25969178
9.

Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa.

Mensch BS, Gorbach PM, Kelly C, Kiepiela P, Gomez K, Ramjee G, Ganesh S, Morar N, Soto-Torres L, Parikh UM.

AIDS Behav. 2015 May 1. [Epub ahead of print]

PMID:
25931240
10.

Tenofovir alafenamide for HIV infection: is less more?

Wyatt C, Baeten JM.

Lancet. 2015 Jun 27;385(9987):2559-60. doi: 10.1016/S0140-6736(15)60725-5. Epub 2015 Apr 15. No abstract available.

PMID:
25890672
11.

Vaginal deployment and tenofovir delivery by microbicide gels.

Gao Y, Yuan A, Chuchuen O, Ham A, Yang KH, Katz DF.

Drug Deliv Transl Res. 2015 Jun;5(3):279-94. doi: 10.1007/s13346-015-0227-1.

12.

Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.

Sepúlveda-Crespo D, Sánchez-Rodríguez J, Serramía MJ, Gómez R, De La Mata FJ, Jiménez JL, Muñoz-Fernández MÁ.

Nanomedicine (Lond). 2015;10(6):899-914. doi: 10.2217/nnm.14.79.

PMID:
25867856
13.

Correction: Musosal effects for tenofovir 1% gel.

Hladik F, Burgener A, Ballweber L, Gottardo R, Vojtech L, Fourati S, Dai JY, Cameron MJ, Strobl J, Hughes SM, Hoesley C, Andrew P, Johnson S, Piper J, Friend DR, Ball TB, Cranston RD, Mayer KH, McElrath MJ, McGowan I.

Elife. 2015 Mar 24;4. doi: 10.7554/eLife.07586. No abstract available.

14.

The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.

Corneli AL, McKenna K, Perry B, Ahmed K, Agot K, Malamatsho F, Skhosana J, Odhiambo J, Van Damme L.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):578-84. doi: 10.1097/QAI.0000000000000525.

PMID:
25761233
15.

Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.

Laeyendecker O, Redd AD, Nason M, Longosz AF, Karim QA, Naranbhai V, Garrett N, Eshleman SH, Abdool Karim SS, Quinn TC.

J Infect Dis. 2015 Feb 23. pii: jiv110. [Epub ahead of print]

PMID:
25712973
16.

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, Palanee T, Nakabiito C, van der Straten A, Noguchi L, Hendrix CW, Dai JY, Ganesh S, Mkhize B, Taljaard M, Parikh UM, Piper J, Mâsse B, Grossman C, Rooney J, Schwartz JL, Watts H, Marzinke MA, Hillier SL, McGowan IM, Chirenje ZM; VOICE Study Team.

N Engl J Med. 2015 Feb 5;372(6):509-18. doi: 10.1056/NEJMoa1402269.

17.

Mucosal effects of tenofovir 1% gel.

Hladik F, Burgener A, Ballweber L, Gottardo R, Vojtech L, Fourati S, Dai JY, Cameron MJ, Strobl J, Hughes SM, Hoesley C, Andrew P, Johnson S, Piper J, Friend DR, Ball TB, Cranston RD, Mayer KH, McElrath MJ, McGowan I.

Elife. 2015 Feb 3;4. doi: 10.7554/eLife.04525. Erratum in: Elife. 2015;4. doi: 10.7554/eLife.07586.

18.

Preexposure prophylaxis: a path forward.

Katz MH.

JAMA Intern Med. 2015 Feb;175(2):255-6. doi: 10.1001/jamainternmed.2014.6798. No abstract available.

19.

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.

Mansoor LE, Abdool Karim Q, Mngadi KT, Dlamini S, Montague C, Nkomonde N, Mvandaba N, Baxter C, Gengiah TN, Samsunder N, Dawood H, Grobler A, Frohlich JA, Abdool Karim SS.

Trials. 2014 Dec 19;15:496. doi: 10.1186/1745-6215-15-496.

20.

Quiz Page January 2015: acute kidney injury in a patient with well-controlled HIV infection.

Lum EL, Huang S, Huang J, Lassman C.

Am J Kidney Dis. 2015 Jan;65(1):A22-5. doi: 10.1053/j.ajkd.2014.07.016. No abstract available.

PMID:
25523807
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk